Clinical Trial Update: Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for masitinib in combination with gemcitabine in advanced/metastatic epithelial ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Ovarian Cancer | Phase 2, Phase 3 | Status: COMPLETED